Trial Profile
A Prospective, Open, Single-arm Phase II Clinical Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma.
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Jul 2022
Price :
$35
*
At a glance
- Drugs Camrelizumab (Primary) ; Dendritic cells (Primary) ; Natural killer cell therapies (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Sintilimab (Primary) ; Tislelizumab (Primary) ; Toripalimab (Primary)
- Indications Carcinoma; Gastrointestinal cancer
- Focus Therapeutic Use
Most Recent Events
- 20 Jul 2022 New trial record